From a poster on ihub: Important Things From Th
Post# of 155615
(Total Views: 796)
Posted On: 08/15/2020 11:10:01 AM
From a poster on ihub:
Important Things From The 10K
1. Production estimates assume no EUAs. Sensible timeline continuing a recent trend of not over promising I like it.
That said if a EUA does come in, of course the company shifts gears immediately.
2. No lawsuits effecting the company. Someone posted a lot of bad information over the last few months about lawsuit this, and pack of lawyers that. 10k showed no lawsuits that will materially effect the company. Nice.
3. Reverse split listed as a risk factor. Board has not voted on a reverse split, Nader has not opined that a reverse split is the way to go. So along with all the other risks it sits in the boiler plate section of risk disclosures.
4. Committed to resubmitting BLA. On track for that with seeking the Type A meeting with the FDA. Who would submit another FDA before seeking guidance? Answer is no one.
5. Financials show secured financing. Debts cleared, cash on hand to operate. Between cash on hand and available shares we can get through to the conservative estimates of getting approval and to market.
6. No revenue is a gimmie start up biotech with no approvals yet. But this is the obvious and inherent risk investing in a start up biotech. So that moot as it's probably one of the first things anyone's due diligence should have turned up.
7. The 10K out on time. I like seeing delieverables met and kept.
Overall I'm happy with the 10K and I'm comfortable if we end up having the long haul.
Another poster: Financial statements are generally prepared with an assumption that the business will remain a going concern. Just like the forward remarks before every C.C., and in financial statements, the worst scenario is always mentioned as a possibility.
Important Things From The 10K
1. Production estimates assume no EUAs. Sensible timeline continuing a recent trend of not over promising I like it.
That said if a EUA does come in, of course the company shifts gears immediately.
2. No lawsuits effecting the company. Someone posted a lot of bad information over the last few months about lawsuit this, and pack of lawyers that. 10k showed no lawsuits that will materially effect the company. Nice.
3. Reverse split listed as a risk factor. Board has not voted on a reverse split, Nader has not opined that a reverse split is the way to go. So along with all the other risks it sits in the boiler plate section of risk disclosures.
4. Committed to resubmitting BLA. On track for that with seeking the Type A meeting with the FDA. Who would submit another FDA before seeking guidance? Answer is no one.
5. Financials show secured financing. Debts cleared, cash on hand to operate. Between cash on hand and available shares we can get through to the conservative estimates of getting approval and to market.
6. No revenue is a gimmie start up biotech with no approvals yet. But this is the obvious and inherent risk investing in a start up biotech. So that moot as it's probably one of the first things anyone's due diligence should have turned up.
7. The 10K out on time. I like seeing delieverables met and kept.
Overall I'm happy with the 10K and I'm comfortable if we end up having the long haul.
Another poster: Financial statements are generally prepared with an assumption that the business will remain a going concern. Just like the forward remarks before every C.C., and in financial statements, the worst scenario is always mentioned as a possibility.
(6)
(0)